Project description:The goal of this study was to investigate the roles of Butyrophilin Subfamily 1 Member A1 (BTN1A1) in terms of the signaling pathway after overexpression of BTN1A1A1 gene. To this end, we conducted NanoString analysis. From NanoString analysis with BTN1A1-overexpressing PC3 cells, we concluded that BTN1A1 play a pivotal role in the regulation of several signaling pathway including Jak-STAT pathway that is involved in processes such as immunity, cell division, cell death and tumor formation.
Project description:Comparison of immune-infiltrated bone marrow samples (n=6) with immune-depleted bone marrow samples (n=17) of pediatric acute myeloid leukemia patients using the Nanostring PanCancer IO 360 panel.
Project description:The 12 recurrent GBM patients were participated. NanoString nCounter pancancer IO 360 panel (750 genes) assay was conducted with GBM patients tissue which was extracted at postoperative after recurrent event. The goal of this study was to extract significant genes which were associated with overall survival (OS) and durable response within AKC-treated recurrent GBM patients.
Project description:To investigate mTDT transcriptional features using the Nanostring pancancer io 360 gene expression panel that consists of 770 unique genes involved in the interplay between the tumor, microenvironment and immune response.
Project description:We performed cancer-immune gene expression analysis on a case series of glioblastoma second surgery samples due to novel enhancement following chemoradiation that were confirmed based on clinico-pathologic outcome as disease progression (PD) or pseudoprogression (psPD). This was accomplished using an nCounter Pancancer 360 IO panel. Our goals were to (1) determine if psPD events could be distinguished from PD events using differences in immune cell activation versus cancer cell proliferation and (2) examine whether samples stratified based on their molecular profile in the same way as documented clinico-pathologic diagnosis.
Project description:Gene expression profiling of a total of 770 genes included in the PanCancer IO 360™ panel+ 20 genes of interest were studied in 198 melanomas cases and correlated to TILS and BRAF600E mutation status